1、Full-Chain Support for Innovation,Chinese Government Continues Its Supporting to the Biopharma Industries,and Implications to the Industry CompaniesFull-Chain Support for Innovation,Chinese Government Continues Its Supporting to the Biopharma Industries,and Implications to the Industry Companies02Ov

2、erview of Chinese Biopharma Industry:Macro Trends and Changes,and Role of R&D as the Fundamental Value Driving Factor of the Industry041Strategies of Biopharma Companies18Key Considerations for Biopharma Enterprises 2234Outlook255Contacts26Footstep of Government Measures:Full-Chain Support for Innov

3、ation11203PrefaceAs one of the Strategic sectors in the Chinese economy,the Chinese biopharma industry experienced a rapid development in the last decade.In the post-pandemic era,facing factors such as economic slowdown and a cooling capital market,Chinese biopharma industry has under pressure in th

4、e past two to three years.The central government has issued the concept of“Full-Chain Support for Innovation”to the industry in 2024 and correspondingly,local governments have launched specific policies for the full-chain support for innovation,aiming to provide a comprehensive policy support frame

5、work across the entire industry value chain for biopharma industry.For the biopharma industry,government support has always been an important factor on its development,especially for the enterprises with strategic transformation into a more innovation driven business.In this context,we have observed

6、 multinational biopharma companies(“MNC”)and Chinese local biopharma companies have begun to take various action plans to leverage the policy benefit for their own benefits.From a broader perspective,the sustained policy stimulus and the signs of economic recovery has increased the confidence of Chi